The Metabolic Classroom with Dr. Ben Bikman

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Summary:
Dr. Bikman explains why losing a large amount of weight can sometimes cause the body's metabolism to slow down more than expected.

He uses contestants from The Biggest Loser as an example. Six years after their dramatic weight loss, many had regained much of the weight, yet their bodies were still burning approximately 500 fewer calories per day than expected for their size. This phenomenon is called metabolic adaptation.

Ben explains how hormones such as leptin, insulin, and thyroid hormone influence this process. As body fat decreases, leptin falls, signaling the brain to increase hunger and conserve energy. The body may also reduce spontaneous movement and other energy-consuming activities, making it increasingly difficult to maintain weight loss.

The encouraging news is that the way someone loses weight can make a difference. Ben reviews research suggesting that lower-carbohydrate diets may help preserve energy expenditure after weight loss, particularly in people who produce more insulin. He also emphasizes the importance of eating sufficient protein, maintaining muscle through resistance training, and staying physically active throughout the day.

The central takeaway is that successful weight loss isn't just about losing pounds—it's about protecting your metabolism and developing habits that make the new weight easier to maintain.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
Hosted on Acast. See acast.com/privacy for more information.

Question? 📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Dr. Bikman explains why micronized progesterone should not be confused with the synthetic progestins historically used in many hormone therapies. Micronized progesterone is chemically identical to the hormone produced naturally by a woman’s ovaries, while synthetic progestins can also activate cortisol- or testosterone-related receptors, potentially affecting insulin sensitivity, blood lipids, and other aspects of metabolic health.

Ben reviews clinical evidence showing that micronized progesterone can effectively protect the uterine lining when estrogen is used while preserving more of estrogen’s favorable metabolic effects. Oral micronized progesterone is also converted into allopregnanolone, which enhances the brain’s calming GABA signaling and may improve sleep. Better sleep itself can support insulin sensitivity, while progesterone may also reduce hot flashes and night sweats that interfere with sleep.

The safety evidence is also encouraging. Compared with some synthetic progestins, micronized progesterone appears more favorable with respect to blood clots, breast cancer risk, and metabolic markers. Ben’s overall conclusion is that for women using menopausal hormone therapy who need progesterone to protect the uterus, micronized progesterone appears to be a metabolically favorable partner to estrogen.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Summary:
Dr. Bikman explains why some people may produce an inadequate GLP-1 response and how insulin resistance could be part of the problem. Because intestinal L cells have insulin receptors, chronically elevated insulin can make these cells insulin resistant, reducing their ability to release GLP-1 and potentially creating a cycle of faster stomach emptying, higher glucose, more insulin, and further impairment of the natural GLP-1 response.

Ben uses this physiology to explain how he believes GLP-1 medications should be used: not simply to produce maximum weight loss, but as a temporary window in which carbohydrate cravings become easier to control. Rather than escalating automatically to the highest tolerated dose, he favors using the lowest dose that makes refined carbohydrates easier to resist while still requiring the person to exercise some choice and discipline. During that window, the goal is to establish meals centered on protein, healthy fats, and whole foods while improving sleep and resistance training.

Ben also addresses concerns about lean-mass loss, explaining that body-composition scans can classify losses of water, glycogen, organ fat, and even the non-fat portion of adipose tissue as “lean mass.” Ultimately, he argues that GLP-1 therapy should have an exit strategy: improve insulin sensitivity, restore the body's own GLP-1 signaling as much as possible, establish sustainable habits, and then work with a clinician to gradually reduce the medication rather than assuming it must be permanent.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:
Continuous glucose monitoring shows how the body handles glucose, but it cannot reveal how much insulin was required to produce that glucose response. By continuously measuring ketones alongside glucose, the new dual sensor may provide an indirect window into insulin activity, fat burning, and metabolic flexibility while also helping people with diabetes detect dangerous ketone elevations earlier.

Summary:
Dr. Ben Bikman explores a new wearable that continuously measures both glucose and ketones. Unlike a traditional continuous glucose monitor, Abbott’s Libre Duo can track beta-hydroxybutyrate (BHB) alongside glucose, providing another window into what is happening metabolically. For people with diabetes, continuous ketone monitoring could provide earlier warning of dangerous ketoacidosis, particularly in people with type 1 diabetes or those using SGLT2 inhibitors.

Ben explains why ketones provide information that glucose alone cannot. Because insulin strongly suppresses fat release, fat oxidation, and ketone production, changes in ketones can serve as an indirect indicator of insulin activity. A seemingly normal glucose response can therefore hide the fact that the body required a large amount of insulin to produce it, while watching glucose and ketones together may reveal more about how readily the body transitions between glucose and fat metabolism.

Ben sees potential value beyond diabetes as well. During fasting or carbohydrate restriction, glucose would generally fall while ketones rise; after a carbohydrate-rich meal, the opposite occurs. Tracking both signals continuously could therefore offer a more complete picture of metabolic flexibility and help people better understand their individual responses to food, fasting, and other metabolic changes.

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

Also, Dr. Bikman’s Digital Mind can interact with you in many languages: https://benbikman.com/ben-bikmans-digital-ai-mind

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.
Hosted on Acast. See acast.com/privacy for more information.

Question?
📢 Ask Dr. Bikman’s Digital Mind (multilingual):
https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

In today’s mini-lecture, Dr. Ben Bikman explains the new generation of oral GLP-1 medications and why two drugs that come as pills can work very differently. Oral semaglutide is still a peptide, so it requires a special absorption enhancer to protect it from digestion and help it cross the stomach lining. Even then, only about 1% of the dose reaches the bloodstream, requiring strict instructions about taking it on an empty stomach. Orforglipron, by contrast, is a small molecule rather than a peptide, allowing it to survive digestion and be absorbed much more efficiently without the same restrictions.

Ben reviews studies comparing the drugs for blood glucose control, weight loss, side effects, and maintaining weight loss after injectable GLP-1 therapy. But he emphasizes that changing the delivery method does not change the underlying metabolic rules: insulin still governs whether fat is stored or released.

Most importantly, Ben argues that GLP-1 medications should be viewed as an opportunity to change metabolic habits rather than simply as long-term weight-loss drugs. Because they can temporarily reduce cravings for sweets and refined carbohydrates, he believes that window should be used to reduce those foods, emphasize protein and fat, and develop habits that can eventually provide an “off-ramp” from the medication..

References:
For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

#GLP1 #GLP1Medications #OralGLP1 #Orforglipron #Semaglutide #WeightLoss #InsulinResistance #Insulin #MetabolicHealth #WeightLossMedication #GLP1WeightLoss #CarbCravings #BloodSugar #Type2Diabetes #Metabolism #LowCarb #DrBenBikman #MetabolicClassroom #MetabolismMatters #HealthScience
Hosted on Acast. See acast.com/privacy for more information.